Back
IngenOx Therapeutics

IngenOx Therapeutics

ingenox.com

IngenOx is a clinical stage company developing innovative drugs and vaccines aimed at re-invigorating the immune response to the most difficult cancers, often referred to as cold tumours. The company was created following the merger of two University of Oxford spinouts - Argonaut Therapeutics (an OSE portfolio company) and Celleron Therapeutics - in December 2022.

What
Life Sciences
When
Dec 2022
CEO
Nicholas La Thangue
Status
Private
Investment
Active
OSE Board Director
Nick Dixon-Clegg
PreviousNext